(Q40466114)

English

Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.

scientific article published on October 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

Sagar Lonial

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Martha Arellano

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Donald Hutcherson

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Amelia Langston

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Christopher Flowers

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

L T Heffner

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Elliott Winton

7

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Mary Jo Lechowicz

8

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Edmund K Waller

9

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

publication date

1 October 2006

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

47

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

2155-2162

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Advanced Hodgkin's disease: ABVD is better, yet is not good enough!

1 reference

https://api.crossref.org/works/10.1080%2F10428190600774923

21 January 2018

Treatment of non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190600774923

21 January 2018

Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190600774923

21 January 2018

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190600774923

21 January 2018

Activity of vinorelbine in gastrointestinal cancers

1 reference

https://api.crossref.org/works/10.1080%2F10428190600774923

21 January 2018

Vinorelbine in the treatment of lymphoma.

1 reference

https://api.crossref.org/works/10.1080%2F10428190600774923

21 January 2018

Vinorelbine: a new promising drug in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1080%2F10428190600774923

21 January 2018

Combined results of two phase II studies of Taxol (paclitaxel) in patients with relapsed or refractory lymphomas

1 reference

https://api.crossref.org/works/10.1080%2F10428190600774923

21 January 2018

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190600774923

21 January 2018

High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190600774923

21 January 2018

Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1080%2F10428190600774923

21 January 2018

Identifiers

10.1080/10428190600774923

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40466114&oldid=1582966235"